Correspondence

DOI: 10.5582/irdr.2023.01074

Reprogramming the future: Capitalizing on *in vitro* embryo culture by advancing stem cell technologies in the fight against rare genetic disorders

Lisha Li[1,2,3,§], Taiwei Zhang[4,§], Zhaozhao Hua[5], Jing Wang[1,2,3], Hongmei Sun[1,2,3], Qian Chen[4], Yiyuan Zhou[4], Ling Wang[1,2,3,*]

[1] Laboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China;
[2] The Academy of Integrative Medicine of Fudan University, Shanghai, China;
[3] Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China;
[4] Research Center of Obstetrical Eugenics, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China;
[5] Department of Obstetrics, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China.

SUMMARY Capitalizing on breakthroughs in reproductive genetics, the utilization of *in vitro* embryo culture and stem cell technologies heralds a transformative era in addressing global challenges posed by rare genetic diseases. These cutting-edge practices illuminate the intricacies of early human development, elucidate the mechanisms behind rare diseases, and guide the development of potential therapies. Balancing this remarkable innovation with necessary ethical considerations, these technologies have the potential to revolutionize the trajectory of rare genetic disorders, transforming the landscape of diagnosis, treatment, and genetic counseling while offering renewed hope for affected individuals and families worldwide.

Keywords embryo engineering, reproductive genetics, genetic disorders, stem cell therapies, ethical balance

Despite continuous advances in embryo engineering and reproductive genetics, the persistence of birth defects remains a significant challenge both nationally and globally. These defects contribute to a substantial portion of the population affected by rare genetic diseases. In fact, more than 80% of these rare disorders have a genetic basis since they are primarily caused by gene mutations (*1*). Among the 6,000+ recognized rare diseases worldwide, nearly half manifest at birth or during childhood, yet only a small fraction of these disorders have effective treatments, as evinced by the fact that specific therapies are currently available for less than 6% of these diseases (*2*). A previous study indicated that there are 16.8 million patients with rare diseases, but given China's population of 1.4 billion, this number is significantly underestimated (*3*). To address this issue, there is a growing need to rely more heavily on assisted reproductive technologies and prenatal diagnosis techniques. These methods play a crucial role in identifying and preventing the transmission of birth defects associated with rare diseases. Assisted reproduction technologies, such as *in vitro* fertilization (IVF) and preimplantation genetic testing (PGT), can help identify embryos carrying specific genetic mutations linked to rare diseases. By selectively transferring unaffected embryos into the uterus, the risk of passing on these genetic diseases to offspring can be significantly reduced (*4*). Indeed, the quality of embryos plays a crucial role in ensuring a healthy pregnancy. As a result, embryo culture has emerged as a significant and challenging research topic in the field of medical research.

Within the field of technology to prevent birth defects, the utilization of *in vitro* embryo culture models is vital. The process of embryogenesis, which involves the development of morphology and function, is remarkably complex and regulated at multiple levels (*5*). By experimentally manipulating and observing embryo development in *in vitro* cultures, we can enhance our understanding of the early stages of human embryogenesis. This, in turn, facilitates research on various aspects, including the mechanisms underlying early human genetic diseases, structural modifications of rare disease genes, and the screening of therapeutics. The use of *in vitro* embryo culture models provides valuable insights into the intricate processes of embryogenesis. It enables researchers to study and comprehend the initial stages of human development, shining light on the underlying mechanisms of rare genetic diseases (*6*). This knowledge can aid in

identifying and understanding structural modifications in genes responsible for rare diseases (*7*). In addition, *in vitro* embryo culture models offer a platform to screen and evaluate potential therapeutics, potentially leading to the discovery of new treatments for these conditions.

Overall, the use of *in vitro* embryo culture models represents a significant advance in technology to prevent birth defects. It contributes to our understanding of early human development and enables critical research on rare genetic diseases, gene modifications, and the screening of potential treatments (*8*). Ultimately, the meticulous nature of embryo *in vitro* culture has revolutionized how we approach reproductive medicine, and especially in the context of rare diseases. Through procedures like preimplantation genetic testing, we can detect and mitigate the risk of passing on these disorders to future generations (*9*). By combining *in vitro* fertilization with PGT, couples with known genetic disorders can make informed decisions about which embryos to implant, greatly reducing the likelihood of having a child affected by a rare disease.

In addition to PGT, embryo *in vitro* culture also allows for other advances in the understanding and management of rare diseases. Researchers can study the development of embryos in a controlled laboratory environment, providing insights into the early stages of human embryogenesis and the mechanisms underlying rare genetic diseases. This knowledge can contribute to the development of more effective treatments. *In vitro* embryo culture is a powerful tool that empowers couples to make informed choices, reduces the reproductive risks associated with rare diseases, and enhances our overall understanding of these conditions (*10*). As research continues to advance in this field, it holds significant promise for improving the outcomes and quality of life for individuals affected by rare genetic diseases and interventions for those individuals (Figure 1).

In vitro culture does offer researchers valuable insights into early human development and can contribute to our understanding of rare genetic diseases. The ability to study embryos in a controlled laboratory environment has resulted in important discoveries, such as those related to Rett syndrome and the *MECP2* gene (*11*). However, the ethical concerns surrounding embryo *in vitro* culture need to be acknowledged. The manipulation and potential discarding of human embryos raise complex ethical questions about the beginning of life, the moral status of the embryo, and the ethical implications of conducting research on embryos. These ethical concerns have led to ongoing debates and discussions in the scientific and wider communities. Various ethical guidelines, regulations, and informed consent processes are in place to ensure that embryo research is conducted responsibly and within the bounds of ethical considerations (*12,13*). Balancing scientific progress with ethical principles is important in order to promoting responsible research practices and public trust in the field of *in vitro* embryo culture.

The future of *in vitro* stem cell culture holds immense promise, particularly in the realm of rare diseases. The unique ability of stem cells to differentiate into various cell types offers tremendous potential for developing novel therapeutic approaches, and especially for diseases for which there are currently no effective treatments (*14*). These cells can serve as invaluable tools in modeling disease pathogenesis and conducting drug screening. One remarkable example is the use of induced pluripotent stem cells (iPSCs), which can be generated from a patient's own cells and reprogrammed into a stem cell-like state (*15*). These iPSCs can then



Figure 1. Visualizing the intersection: rare diseases, stem cells, and assisted reproductive technologies. This diagram encapsulates the prevalence of rare diseases in China, the importance of *in vitro* embryo culture, the utility of embryonic and induced pluripotent stem cells in disease modeling and drug screening, and the potential of combining these with assisted reproductive technologies such as IVF and preimplantation genetic testing. The interconnected circles highlight the synergy of these elements in addressing rare genetic disorders in the field of reproductive medicine.

be differentiated into the specific cell type affected by the rare disease. This groundbreaking technology has already been used to successfully model numerous rare diseases in laboratory settings, providing unprecedented insights into the underlying cellular and molecular mechanisms at play. Moreover, stem cell research opens up possibilities for regenerative therapies. By utilizing stem cells from patients, damaged tissues could potentially be replaced with healthy cells, leading to a transformative approach in treating rare diseases (*16*).

As research in *in vitro* stem cell culture advances, ethical considerations need to continue to be made, appropriate regulations need to be enacted, and informed consent processes need to be followed to maintain public trust. These combined efforts will undoubtedly contribute to the continued progress and potential of stem cell research in addressing rare diseases. The use of *in vitro* stem cell culture for the targeted treatment of rare diseases holds immense potential, but it also presents several significant challenges that need to be addressed. While regenerative medicine offers great promise, much research still needs to be conducted to fully understand how to reliably guide stem cells in their differentiation process and to ensure their safe integration into the patient's body. Overcoming these challenges will require continued scientific advances and rigorous testing to ensure the efficacy and safety of stem cell therapies.

Ethical considerations and regulatory frameworks also play a vital role in the use of stem cell research (*17*). The use of specific types of stem cells may raise ethical concerns, and careful consideration must be given to ensure that research is conducted within ethical boundaries and adheres to established regulations and guidelines (*18*). Another obstacle to widespread implementation is the complexity and cost associated with creating and differentiating iPSCs. These complexities may limit accessibility and hinder the potential reach of emerging treatments, particularly in settings with limited resources. To overcome this, efforts are underway to develop more efficient and cost-effective techniques for generating and differentiating stem cells.

In conclusion, the utilization of *in vitro* embryo culture in the fight against rare genetic disorders holds immense promise. By capitalizing on pluripotent stem cells and gene therapy techniques, this innovative approach has the potential to revolutionize the diagnosis, modeling, and treatment of these conditions (*19*). Ongoing ethical discussions, combined with efforts to improve accessibility, will play a crucial role in shaping the future of *in vitro* embryo culture and its impact on rare genetic disorders.

Funding: This work was supported by four projects of the National Natural Science Foundation of China (grant no. 82374243 to L Wang, grant no. 82304906 to LL Li, grant no. 82060881 to TW Zhang, grant no. 82260950 to YY Zhou).

Conflict of Interest: The authors have no conflicts of interest to disclose.

References

1. Lu Y, Han J. The definition of rare disease in China and its prospects. Intractable Rare Dis Res. 2022; 11:29-30.
2. He J, Kang Q, Hu J, Song P, Jin C. China has officially released its first national list of rare diseases. Intract & Rare Dis Res. 2018; 7:145-147.
3. Li X, Liu M, Lin J, Li B, Zhang X, Zhang S, Lu Z, Zhang J, Zhou J, Ou L. A questionnaire-based study to comprehensively assess the status quo of rare disease patients and care-givers in China. Orphanet J Rare Dis. 2021; 16:327.
4. Sciorio R, Tramontano L, Catt J. Preimplantation genetic diagnosis (PGD) and genetic testing for aneuploidy (PGT-A): Status and future challenges. Gynecol Endocrinol. 2020; 36:6-11.
5. Aguilera-Castrejon A, Oldak B, Shani T, et al. Ex utero mouse embryogenesis from pre-gastrulation to late organogenesis. Nature. 2021; 593:119-124.
6. Briand N, Guénantin AC, Jeziorowska D, Shah A, Mantecon M, Capel E, Garcia M, Oldenburg A, Paulsen J, Hulot JS, Vigouroux C, Collas P. The lipodystrophic hotspot lamin Ap.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks. Hum Mol Genet. 2018; 27:1447-1459.
7. Ganassi M, Zammit PS. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies. Eur J Transl Myol. 2022; 32:10064.
8. Balak JRA, Juksar J, Carlotti F, Lo Nigro A, de Koning EJP. Organoids from the human fetal and adult pancreas. Curr Diab Rep. 2019; 19:160.
9. Yan L, Huang L, Xu L, Huang J, Ma F, Zhu X, Tang Y, Liu M, Lian Y, Liu P, Li R, Lu S, Tang F, Qiao J, Xie XS. Live births after simultaneous avoidance of monogenic diseases and chromosome abnormality by next-generation sequencing with linkage analyses. Proc Natl Acad Sci USA. 2015; 112:15964-15969.
10. Balaban B, Urman B. Embryo culture as a diagnostic tool. Reprod Biomed Online. 2003; 7:671-682.
11. Liyanage VR, Rastegar M. Rett syndrome and MeCP2. Neuromolecular Med. 2014; 16:231-264.
12. Lovell-Badge R, Anthony E, Barker RA, et al. ISSCR guidelines for stem cell research and clinical translation: The 2021 update. Stem Cell Reports. 2021; 16:1398-1408.
13. Nicolas P, Etoc F, Brivanlou AH. The ethics of human-embryoids model: A call for consistency. J Mol Med (Berl). 2021; 99:569-579.
14. Golchin A, Chatziparasidou A, Ranjbarvan P, Niknam Z, Ardeshirylajimi A. Embryonic stem cells in clinical trials: Current overview of developments and challenges. Adv Exp Med Biol. 2021; 1312:19-37.
15. Ohnuki M, Takahashi K. Present and future challenges of induced pluripotent stem cells. Philos Trans R Soc Lond B Biol Sci. 2015; 370:20140367.
16. Bourque K, Hawey C, Jiang A, Mazarura GR, Hébert TE. Biosensor-based profiling to track cellular signalling in

patient-derived models of dilated cardiomyopathy. Cell Signal. 2022; 91:110239.
17. Liras A. Future research and therapeutic applications of human stem cells: General, regulatory, and bioethical aspects. J Transl Med. 2010; 8:131.
18. Hurlbut WB. Ethics and embryonic stem cell research: Altered nuclear transfer as a way forward. BioDrugs. 2007; 21:79-83.
19. De Masi C, Spitalieri P, Murdocca M, Novelli G, Sangiuolo F. Application of CRISPR/Cas9 to human-induced pluripotent stem cells: From gene editing to drug discovery. Hum Genomics. 2020; 14:25.

Received August 28, 2023; Revised May 16, 2024; Accepted May 22, 2024.

[§]These authors contributed equally to this work.
**Address correspondence to:*
Ling Wang, Laboratory for Reproductive Immunology, Obstetrics and Gynecology Hospital of Fudan University, 419 Fangxie Road, Shanghai 200011, China.
E-mail: dr.wangling@fudan.edu.cn

Released online in J-STAGE as advance publication May 24, 2024.